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Four-and-a-half LIM-only protein 2 (FHL2) is an important mediator in many signaling pathways. In this study, we analyzed the
functions of FHL2 in nuclear factor B (NF-B) signaling in the liver. We show that FHL2 enhanced tumor necrosis factor
(TNF) receptor-associated factor 6 (TRAF6) activity in transcriptional activation of NF-B targets by stabilizing the protein.
TRAF6 is a binding partner of FHL2 and an important component of the Toll-like receptor–NF-B pathway. Knockdown of
FHL2 in 293-hTLR4/MD2-CD14 cells impaired lipopolysaccharide (LPS)-induced NF-B activity, which regulates expression of
inflammatory cytokines. Indeed, FHL2/ macrophages showed significantly reduced production of TNF and interleukin 6
(IL-6) following LPS stimulation. TNF and IL-6 are the key cytokines that prime liver regeneration after hepatic injury. Follow-
ing partial hepatectomy, FHL2/ mice exhibited diminished induction of TNF and IL-6 and delayed hepatocyte regeneration.
In the liver, NF-B signaling orchestrates inflammatory cross talk between hepatocytes and hepatic immune cells that promote
chemical hepatocarcinogenesis. We found that deficiency of FHL2 reduced susceptibility to diethylnitrosamine-induced hepato-
carcinogenesis, correlating with the activator function of FHL2 in NF-B signaling. Our findings demonstrate FHL2 as a positive
regulator of NF-B activity in liver regeneration and carcinogenesis and highlight the importance of FHL2 in both hepatocytes
and hepatic immune cells.
Four-and-a-half LIM-only protein 2 (FHL2) plays importantroles in cell proliferation, apoptosis, and transformation (1).
Endowed with a unique structure exclusively composed of 4.5
LIM domains for protein-protein interaction, FHL2 has been
shown to interact with more than 50 cellular partners involved in
almost all major signaling pathways that govern essential cellular
processes. In hormone signaling, FHL2 is the transcriptional co-
activator of both androgen and estrogen receptors (2, 3). In the
transforming growth factor  (TGF-) pathway, FHL2 interacts
with Smad proteins (4), the transcription repressor Ski (5), and
the E3 ligase Arkadia (6) and plays the role of the positive regulator
in response to TGF- signaling. FHL2 is a serum-inducible coacti-
vator of the transcription factor AP1 (7), the downstream effector
of receptor tyrosine kinase-initiated signaling cascades. In Wnt/-
catenin signaling, FHL2 exerts both transcription corepressor and
coactivator functions of-catenin, depending on the cellular con-
text (8–11). The main receptor of Sonic hedgehog Patched re-
cruits a proapoptotic complex containing FHL2 and caspase 9 and
triggers cell death through a caspase 9-dependent mechanism
(12). In the Toll-like receptor (TLR)/tumor necrosis factor (TNF)
signaling, FHL2 interacts with TNF receptor-associated factor 2
(TRAF2), TRAF4, and TRAF6 (13), which are key mediators in the
signal transduction mechanisms that activate the nuclear factor
B (NF-B) signaling pathway.
NF-B transcription factors are master regulators of immu-
nity, inflammation, cell survival, and proliferation (14). In steady-
state conditions, NF-B is inactive in the cytoplasm through as-
sociation with the inhibitor of B (IB) proteins. Upon induction
by signals ranging from proinflammatory cytokines to cell stress
to pathogen-associated molecular patterns, IB proteins undergo
phosphorylation, ubiquitination, and degradation, releasing
NF-B for translocation to the nucleus, where NF-B family
members form homodimers or heterodimers to bind specific
DNA sequences and promote transcription of target genes encod-
ing cytokines, chemokines, and survival and growth factors (15).
The relationship between FHL2 and NF-B is highly cell con-
text dependent. During osteoclast formation stimulated by the
receptor activator of NF-B (RANK) ligand, FHL2 inhibits
TRAF6-induced NF-B activity (13). In muscle cells, FHL2 en-
hances production of interleukin 6 (IL-6) through activation of
NF-B and p38 signaling pathways (16). In HEK293 cells, FHL2
induces TRAF2-mediated activation of NF-B by counteracting
the suppressive effects of Tucan/Cardinal on NF-B (17). The
NF-B signaling pathway is crucial for liver biology and disease
(18). Knockout of the RelA/p65 component of NF-B, IB kinase
 (IKK), or IKK in mice results in embryonic lethality due to
liver apoptosis (19, 20). Deregulation of NF-B signaling through
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conditional deletion of IKK or IKK or expression of a nonde-
gradable form of IB in the liver leads to either enhancement or
inhibition of the development of hepatocellular carcinoma
(HCC) (21–23).
We have recently reported that enhanced expression of FHL2
in hepatocytes increases both cell proliferation and apoptosis and
promotes liver tumorigenesis associated with activation of the
Wnt/-catenin signaling (24). Given the crucial functions of
NF-B in innate immunity and inflammation, we hypothesized
that FHL2 might also have a role in liver hepatic immune cells
through its implication in NF-B signaling. Here, we used consti-
tutive FHL2 knockout mice to investigate the relationship be-
tween FHL2 and NF-B signaling in liver regeneration and carci-
nogenesis. We report that deletion of FHL2 suppresses in vitro and
in vivo an array of NF-B-mediated effects, including cytokine
expression, hepatocyte proliferation, and chemical carcinogen-
induced HCC. The underlying mechanisms involve regulation of
TRAF6 expression by FHL2. Our findings provide evidence of the
requirement of FHL2 for activation of NF-B signaling in the
liver.
MATERIALS AND METHODS
Animals. FHL2/ mice on the Black Swiss–129-SV/J background (25)
were backcrossed into C57BL/6J mice over more than eight generations.
For partial hepatectomy, F1 FHL2/ and FHL2/ littermates generated
by intercrossing FHL2/ mice were used. For diethylnitrosamine
(DEN)-induced tumorigenesis, F2 mice were used. F2 FHL2/ mice
were generated by intercrossing F1 FHL2/ littermates. F2 wild-type
(wt) mice were generated by intercrossing F1 FHL2/ littermates. All
experiments were performed with age- and sex-matched animals. Wild-
type and FHL2/ animals were housed in the same room in a pathogen-
free environment at the Institut Pasteur animal facility and received hu-
mane care according to the criteria outlined in the Guide for the Care and
Use of Laboratory Animals. Experimental procedures were carried out in
accordance with French government regulations.
Surgical procedures and treatments. Animal experiments were car-
ried out according to the European Union directives for animal experi-
mentation (decree 2001-131 published in the Journal Officiel 6 February
2001). Two-thirds hepatectomy was performed on adult male mice (8 to
12 weeks old) as described previously (26). Four to eight animals of each
genotype were sacrificed at each time point posthepatectomy. To analyze
hepatocyte proliferation, animals were injected intraperitoneally with
bromodeoxyuridine (BrdU; 50 mg/kg of mouse body weight) 2 h before
livers were harvested. After removal of the liver, part of the remnant liver
lobes was fixed immediately in paraformaldehyde (PFA) and stained for
BrdU. BrdU-positive cell nuclei were counted on 5 consecutive high-
power fields in three animals of each genotype. Others were frozen in
nitrogen and stored at 80°C. For cytokine assay on liver homogenates,
livers removed from mice 1 h after partial hepatectomy (PH) were
weighed and then homogenized with glass beads in 1 ml phosphate-buff-
ered saline (PBS) using the Mixer Mill MM301 (Retsch). After centrifu-
gation, supernatants were collected for TNF and IL-6 measurement by
enzyme-linked immunosorbent assay (ELISA). Values were normalized
to liver weight.
To analyze cytokine production in Kupffer cells, wt and FHL2/
animals were fed a diet devoid of methionine-choline (MCD) (Scientific
Animal Food & Engineering [SAFE]) for 2 weeks.
Immunohistochemistry and apoptosis detection. Immunohisto-
chemistry (IHC) was described previously (24). Primary antibodies in-
clude BrdU (Dako), Ki-67 (Novocastra), and F4/80 (BM8) (Santa Cruz
Biotechnology) (dilution, 1:100). Sections were probed with secondary
antibodies using the Impress kit (Vector Laboratories). Revelation was
performed using the 3,3=-diaminobenzidine (DAB) substrate detection
kit (Vector Laboratories). Slides were counterstained with Mayer’s hema-
toxylin solution.
Apoptosis was detected by terminal deoxynucleotidyltransferase-me-
diated dUTP-biotin nick end labeling (TUNEL). TUNEL-positive cells
were counted on 6 to 10 consecutive high-power fields in three animals of
each genotype.
Cell culture, reagents, and reporter assay. 293T, 293-hTLR4/MD2-
CD14 (InvivoGen), HEK293 cell lines expressing TLR4/MD2-CD14 and
mouse embryonic fibroblasts (MEF) (27) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS).
HepG2 cells were cultured in DMEM–F-12 with 3.5 107 M hydrocor-
tisone and insulin (5g/ml). For reporter assays, 3 105 cells were plated
in six-well plates and transfected using Lipofectamine 2000 (Invitrogen)
with expression vectors coding for FHL2, TRAF6, or TRAF6 mutant
C70A, Rel/p65, and luciferase reporter containing wt or mutated NF-B-
responsive elements. Luciferase activity was determined 48 h later. A re-
nilla plasmid under the control of thymidine kinase was used as the inter-
nal control, and the total DNA amount in each transfection was kept
constant by adding an empty vector. All experiments were performed in
duplicate and repeated at least three times. FHL2 expression in 293-
hTLR4/MD2-CD14 cells and TRAF6 expression in 293T cells were inhib-
ited by lentiviral transduction of FHL2 or TRAF6 short hairpin RNA
(shRNA) (Santa Cruz Biotechnology), respectively, followed by selection
with puromycin. Lipopolysaccharide (LPS) TLRgrade (ALX-581-012-
L002; Alexis Biochemicals) (1g/ml) was used to stimulate FHL2-knock-
down and control 293-hTLR4/MD2-CD14 cells for 18 h.
Protein analysis. Livers were homogenized in lysis buffer containing
50 mM Tris-HCl (pH 8), 200 mM NaCl, 0.1 mM EDTA, 0.5% NP-40, 10%
glycerol, and protease inhibitors. For nuclear extraction, MEFs were lysed
in 10 mM HEPES (pH 7.8), 10 mM KCl, 1.5 mM MgCl2, 1 mM dithio-
threitol (DTT), 10% NP-40, and protease inhibitors. After centrifugation,
the pellet was resuspended in 400 mM KCl, 50 mM Tris (pH 8), 0.5%
NP-40, 1 mM DTT, and protease inhibitors and incubated for 45 min. The
nuclear membrane was eliminated by centrifugation. After quantification
with Bradford protein assay, equal amounts of protein extract were ana-
lyzed by immunoblotting. 293T cells transfected or not with FHL2 were
lysed in Laemmli buffer, and protein extracts were resolved in 4 to 12%
polyacrylamide gels (Invitrogen) and transferred to Hybond-C extra
(Amersham Pharmacia Biotech). Primary antibodies include TRAF6,
STAT3, phospho-STAT3, phospho-p65 (S536) (Cell Signaling), p65,
PCNA, cyclin-dependent kinase 2 (CDK2), CDK4, and cyclin A (Santa
Cruz Biotechnology), FHL2 (MBL), and actin and tubulin (Sigma-Al-
drich). Signal intensities of nuclear p65 were scanned and quantified by
using the LI-COR/Odyssey infrared image system. To determine TRAF6
turnover, 293T cells were treated with 100 g/ml cycloheximide (Sigma-
Aldrich) and harvested at the indicated times. Signal intensities were
scanned and quantified by using NIH ImageJ software as described pre-
viously (28).
Cytokine assay. Bone marrow-derived macrophages (BMDMs) were
prepared from wt and FHL2/ mice as described previously (29) and
stimulated for differentiation with 400 u/ml macrophage colony-stimu-
lating factor (M-CSF). A total of 1  106 adherent BMDMs plated in
six-well plates were cultured in RPMI with 10% heat-inactivated FBS and
then induced with 1 g/ml LPS for 24 h. TNF and IL-6 were measured in
supernatants with ELISA as specified by the manufacturer (DuoSet, R&D
Systems, Minneapolis, MN).
Kupffer cells were isolated from animals on MCD or normal diets as
described previously (30). TNF and IL-6 were measured in supernatants
with ELISA.
RNA analysis. Total RNA was extracted from Kupffer cells or homog-
enized liver tissues using TRIzol (Invitrogen). RNA (1 g) was reverse
transcribed using random primers (Promega) and RevertAid HMinus
reverse transcriptase (Fermentas). The relative levels of mRNAs were de-
termined by real-time PCR using fast-start universal SYBR green (Roche).
The mean copy number of each gene from a triplicate determination was
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normalized to the mean copy number of hypoxanthine-guanine phos-
phoribosyltransferase (HPRT). The following primers were used for real-
time PCR: FHL2, 5=-GTCCTACAAGGATCGGCACT-3=, 5=-ACAGGTG
AAGCAGGTCTCGT-3=; HPRT, 5=-ATGCCGAGGATTTGGAAAAA-3=,
5=-ACAATGTGATGGCCTCCCA-3=; TLR4, 5=-AACAAGAAACGGCAA
CTTGGA-3=, 5=-CCATAGCAGAGCCCCAGGT-3=; IL-6, 5=-TTGCCTT
CTTGGGACTGATGCT-3=, 5=-GTATCTCTCTGAAGGACTCTGG-3=;
TNF, 5=-GTGACCTGGACTGTGGGCCTC-3=, 5=-GGCTCTGTGAGGA
AGGCTGTG-3=.
Statistical analysis. A chi-square test was used for statistical analysis of
tumor incidence. Student’s t test was used for other statistical analysis. The
significant level was defined as P values of	0.05.
Tumor induction and analysis. Fourteen-day-old mice were injected
intraperitoneally with 25 mg/kg DEN (Sigma) and sacrificed 3 h, 6 h, 15 h,
24 h, 48 h, or 8 months later. Livers were removed for RNA, protein, IHC,
and TUNEL analyses.
Blood analysis. Blood samples were collected from mice, followed by
centrifugation. Insulin, glucose, aspartate aminotransferase (ASAT), and
triglyceride were measured in plasma by Vebiotel Laboratory (Arcueil, Val
de Marne, France). A total of 30 l of whole-blood samples was used for
counting cell numbers with a vet ABC automat.
RESULTS
FHL2/ mice exhibit diminished regeneration response after
partial hepatectomy. A previous study showed that overexpres-
sion of FHL2 in hepatocytes accelerated liver regeneration (24).
To further investigate the role of FHL2 in liver regeneration, we
performed a partial hepatectomy (PH) on FHL2/mice and sac-
rificed the mice at different time points to examine hepatocyte
proliferation. BrdU incorporation demonstrated lower levels in
DNA synthesis at 24 h and 48 h after PH in FHL2/ mice than in
wt mice but similar levels in DNA synthesis at 72 h and 96 h after
PH between wt and FHL2/ mice (Fig. 1A and B and data not
shown). TUNEL analysis revealed no significant difference of
apoptosis in regenerating livers from FHL2/ and wt animals
FIG 1 Delayed liver regeneration in FHL2/mice after partial hepatectomy (PH). (A) Immunohistochemistry on liver sections from wt and FHL2/mice 24
h and 48 h after PH with BrdU antibody. (B) Delayed DNA synthesis after PH in FHL2/ liver as determined by BrdU incorporation. Asterisks indicate
significant differences between FHL2/ and wt animals. ***, P	 0.0005. (C) Apoptosis was detected by TUNEL. Quantification of TUNEL-positive cells in wt
and FHL2/ livers 0 h, 1 h, 24 h, 48 h, or 72 h after PH. ns, not significant. (D) Immunoblotting analysis of cell cycle regulators and phosphorylation of NF-B
p65 on S536. (E) TNF and IL-6 in wt and FHL2/ livers 1 h after PH, as evaluated by ELISA. *, P 	 0.05; **, P 	 0.005; ***, P 	 0.0005. (F) Reduced
phosphorylation of STAT3 in FHL2/ livers 1 h after PH. Proteins extracted from wt and FHL2/ livers 1 h after PH were analyzed by Western blotting.
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(Fig. 1C). While cell cycle regulators cyclin D1, cyclin A, CDK2,
CDK4, and PCNA were not significantly different between wt and
FHL2/ regenerating livers, the levels of NF-B p65 phosphory-
lation at S536, indicative of NF-B activation, were lower in
FHL2/ livers at 24 h and 48 h after PH (Fig. 1D). FHL2/mice
eventually restored the same liver weight as wt mice 8 days after
PH. These results showed that liver regeneration was delayed in
FHL2/ mice after PH. TNF and IL-6 are major cytokines for
priming normally quiescent hepatocytes to enter the cell cycle in
response to hepatic injury (31, 32). Examination of cytokine pro-
duction 1 h after operation showed that TNF and IL-6 were ex-
pressed at dramatically lower levels in regenerating livers of
FHL2/ mice than those of wt mice (Fig. 1E). IL-6 stimulates
compensatory hepatocyte proliferation through activation of the
signal transducer and activator of transcription 3 (STAT3). Ac-
cordingly, immunoblotting analysis revealed reduced phosphor-
ylation of STAT3 in FHL2/ livers compared to wt counterparts
at 1 h after PH (Fig. 1F). Overall, these findings suggest that loss of
FHL2 impairs cytokine production and affects cytokine-regulated
early proliferative response to hepatic injury.
Histological analysis of the FHL2-deficient liver revealed no
notable anomaly (Fig. 2A) and no HCC after 2 years of observa-
tion. FHL2/ mice show no spontaneous liver dysfunction, as
attested by the absence of significant alterations in serum insulin,
glucose, aspartate aminotransferase (ASAT), and triglyceride (Fig.
3A). Kupffer cells are the major cytokine producer in the liver.
F4/80 immunostaining showed morphology and percentage of
Kupffer cells similar to parenchymal cells between wt and
FHL2/ livers (Fig. 2B and C). Analysis by real-time PCR on
RNA from Kupffer cells isolated from wt mice confirmed expres-
sion of FHL2 in this specific cell type (Fig. 2D). In addition, no
difference was observed in cell composition in peripheral blood
between wt and FHL2/ mice (Fig. 3B). To assess the impact of
FHL2 deficiency on cytokine production by Kupffer cells, we fed
wt and FHL2/ animals an MCD, which is known to induce
steatosis-associated inflammation (33, 34). Kupffer cells isolated
from animals on an MCD or control mice were cultured in vitro,
and TNF and IL-6 in the supernatant were measured by ELISA.
Remarkably, even though TNF and IL-6 were elevated in both wt
and FHL2/ Kupffer cells from animals on an MCD, their levels
were significantly lower in FHL2/ cells (Fig. 2E). Taken to-
gether, these results suggest that deficiency of FHL2 may affect
signaling pathways that control cytokine expression.
FHL2 deficiency decreases LPS-induced cytokine production
in macrophages. NF-B signaling plays a central role in initiation
of liver regeneration, as it promotes production of TNF and IL-6
(31). Lipopolysaccharide (LPS) is one of the important molecules
for activation of NF-B after PH (35), because liver injury pro-
vokes an increase of LPS levels originating from commensal intes-
tinal bacteria. To examine the role of FHL2 in NF-B activation
induced by LPS, we knocked down FHL2 in 293-hTLR4/MD2-
CD14 cells (Fig. 4A), which express the hTLR4/MD2-CD14 recep-
tor complex for LPS, and transfected it with the NF-B wt reporter
or a reporter mutated at the NF-B responsive element, followed
by stimulation with LPS. While LPS potently activated NF-B
reporter in control cells, knockdown of FHL2 reduced the LPS-
mediated NF-B reporter activation by half (Fig. 4B). No effect of
LPS was observed on the mutated NF-B responsive elements
(Fig. 4B). NF-B regulates transcriptional programs that induce
genes coding for cytokines, including TNF and IL-6. To assess the
effects of FHL2 on NF-B-mediated cytokine production, bone
marrow-derived macrophages isolated from wt and FHL2/
mice were stimulated for differentiation with M-CSF, followed by
treatment with LPS. TNF and IL-6 in the supernatant were mea-
sured by ELISA. Significant reduction of TNF and IL-6 was ob-
served in FHL2/ macrophages after LPS stimulation (Fig. 4C),
even though similar expression levels of TLR4 were detected in
FHL2/ and wt cells (Fig. 4D). To exclude the possibility that
mice lacking FHL2 may harbor pathogens that elicit immune tol-
erance to LPS, we tested sera from wt or FHL2/ mice in the
TLR4 reporter cell line for screening LPS, which can be recognized
by TLR4. None of the sera elicited any response in the line (data
not shown). Taken together, these findings show that FHL2 might
be required for triggering NF-B-mediated cytokine production.
FIG 2 Loss of FHL2 has no effect on liver organization. (A) H&E shows
hematoxylin and eosin staining of liver tissues. (B) Immunostaining of Kupffer
cells with F4/80 antibody. (C) Quantification of Kupffer cells in wt and
FHL2/ livers. (D) Analysis of FHL2 expression by real-time reverse tran-
scription (RT)-PCR in Kupffer cells isolated from wt and FHL2/ mice. (E)
TNF and IL-6 in wt and FHL2/ Kupffer cells from animals on an MCD or a
normal diet, as evaluated by ELISA. *, P	 0.05; ***, P	 0.0005.
Dahan et al.
3302 mcb.asm.org Molecular and Cellular Biology
FHL2 participates in NF-B signaling through TRAF6. FHL2
interacts with both cytoplasmic and nuclear proteins and is a co-
factor of many transcription factors. We next examined whether
FHL2 could synergize with NF-B transcription factor in regula-
tion of transcription by coexpressing FHL2 and p65 in the hepa-
toma cell line HepG2. FHL2 effectively potentiated p65 activity
(Fig. 5A). However, we did not detect interaction between FHL2
and p65. We thus tested if FHL2 had impacts on NF-B translo-
cation. Wild-type or FHL2/ mouse embryonic fibroblasts
(MEF) were stimulated with LPS, and nuclear p65 expression was
analyzed by immunoblotting. Deletion of FHL2 delayed nuclear
translocation of NF-B (Fig. 5B and C), suggesting that the effect
of FHL2 on NF-B is achieved mainly in the cytoplasm. It has been
reported that FHL2 interacts with TRAF6 (13), an E3 ubiquitin
ligase essential for the activation of NF-B. To investigate the
cooperation of FHL2 with TRAF6, we transfected the NF-B lu-
ciferase reporter in combination with FHL2 and TRAF6 in 293T
cells. Overexpression of wt TRAF6, but not the C70A mutant lack-
ing E3 activity, readily activated NF-B-dependent transcription
(Fig. 5D, lanes 5 and 9), in agreement with previous reports (33–
35). Strikingly, whereas FHL2 alone had a barely detectable effect
on NF-B reporter activity (Fig. 5D, lanes 2 to 4), it cooperated
with wt TRAF6 but not the C70A mutant to enhance NF-B sig-
naling in a dose-dependent manner (Fig. 5D, lanes 6 to 8 and 10).
Next, we knocked down TRAF6 in 293T cells and carried out
NF-B luciferase reporter assay in these cells. The activity of FHL2
on the NF-B reporter was significantly diminished in TRAF6-
knocked-down cells (Fig. 5E), indicating that TRAF6 is required
for FHL2 to fully exert its function in activation of NF-B signal-
ing. To elucidate the mechanisms of FHL2 and TRAF6 coopera-
FIG 3 (A) Circulating insulin, glucose, aspartate aminotransferase (ASAT), and triglyceride levels in serum from 3-month-old wt and FHL2/ mice. Each
symbol represents one individual. (B) Full blood counts in 3-month-old wt and FHL2/ mice. Each symbol represents one individual.
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tion, we assessed the impact of FHL2 on the stability of endoge-
nous TRAF6 by transfecting FHL2 in 293T cells, followed by
blocking protein synthesis with cycloheximide. Overexpression of
FHL2 resulted in an increase in the stability of endogenous TRAF6
(Fig. 5F and G). These findings suggest that FHL2 participates in
NF-B signaling most likely via its ability to interact with the
pathway component TRAF6.
Loss of FHL2 reduces susceptibility to DEN-induced liver
carcinogenesis. NF-B activation is intimately linked to hepato-
carcinogenesis (36). A previous report demonstrated that hepato-
cyte-specific depletion of IKK increased carcinogenesis induced
by the hepatic carcinogen diethylnitrosamine (DEN), whereas de-
letion of IKK in both hepatocytes and nonparenchymal cells
reduced DEN-induced tumorigenesis (21). It has been argued that
inactivation of NF-B through deletion of IKK diminished in-
duction of hepatomitogens in hepatic hematopoietic-derived
cells, resulting in reduced compensatory proliferation of hepato-
cytes and thus tumorigenesis (21). As FHL2/ mice exhibited
diminished cytokine production in response to hepatic injury, we
asked whether constitutive deletion of FHL2 might have similar
effects as IKK deletion on carcinogenesis. To address it, we used
the DEN model for liver carcinogenesis by injecting the chemical
carcinogen into 14-day-old wt and FHL2/mice. As expected for
wt mice, all males (8/8) developed HCCs within 8 months, versus
45.4% females with HCCs (5/11) (Table 1). Interestingly, tumor
incidence was significantly lower in both FHL2/ males (P 	
0.0005) and females (P 	 0.005) than in wt mice, as only 71.4%
male (10/14) and 18.7% female (3/16) animals deficient for FHL2
developed tumors (Table 1). Histopathological analysis revealed
HCCs of various sizes, most often multifocal and randomly dis-
tributed in the liver parenchyma in both wt and FHL2/ mice
(Fig. 6A to F). Tumors were well demarcated but not encapsu-
lated, focally invading the remaining parenchyma (Fig. 6C and D).
Tumor cells were mostly organized in nests and trabeculae, rarely
in tubules, with lipids in the cytoplasm and giant nucleoli (Fig. 6E
and F). Anisocytosis, anisokaryosis, and cellular atypia were fre-
quent (data not shown). No vascular invasion was observed. Al-
though not significant, FHL2 expression was enhanced in tumor
tissues from wt mice (Fig. 6G). These data indicate that loss of
FHL2 decreases susceptibility to DEN-induced hepatocarcino-
genesis.
DEN-induced HCC requires NF-B-dependent production of
IL-6 by Kupffer cells and the activation of STAT3 by IL-6 in hepa-
tocytes (37, 38). We compared early effects of DEN on IL-6 and
TNF expression in wt and FHL2/ livers and observed a trend
but not a significant decrease of IL-6 in FHL2/ mice at the 3-h
time point (Fig. 7A). FHL2 expression was not enhanced by DEN
administration in wt mice (Fig. 7A). Analysis of STAT3 activation
by immunoblotting revealed delayed and reduced phosphoryla-
tion of STAT3 in FHL2/ mice (Fig. 7B), suggesting that FHL2
deficiency affects the IL-6/STAT3 axis in the DEN model. Ki-67
immunostaining demonstrated a lower number of proliferating
hepatocytes in FHL2/ mice than wt mice 24 h and 48 h after
DEN exposure (Fig. 7C and D). Moreover, FHL2/ mice exhib-
FIG 4 FHL2 deficiency results in diminished induction of cytokines TNF and IL-6 by LPS. (A) Knockdown of FHL2 in 293-hTLR4/MD2-CD14 cells.
293-hTLR4/MD2-CD14 cells were transduced with either control (shCtl) or FHL2 shRNA (shFHL2) lentiviral vectors. FHL2 expression was analyzed by
Western blotting. (B) Reporter assay in 293-hTLR4/MD2-CD14 cells transduced with the control or FHL2 shRNA lentiviral vector. Cells were transfected
with either NF-B wt reporter (WT) or reporter in which the NF-B responsive element is abolished (mu). Cells were stimulated with 1 g/ml LPS for
18 h. The basal activity of the NF-B wt reporter in cells transduced with shCtl without LPS stimulation was arbitrarily set at 1. Data are presented as mean
induction in luciferase activity 
 standard deviation (SD) from duplicate samples. The results shown are representative of those from more than three
independent assays. RNAi, RNA interference. ***, P	 0.0005. (C) Bone marrow-derived macrophages (BMDM) isolated from wt and FHL2/mice were
stimulated with 1 g/ml LPS for 24 h. TNF and IL-6 were measured by ELISA. *, P 	 0.05; ***, P 	 0.0005. (D) Analysis of TLR4 expression in BMDM
cells by real-time RT-PCR. The level of TLR4 in wt cells was arbitrarily set as 1.
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FIG5 FHL2 cooperates with TRAF6 in activation of NF-B. (A) HepG2 cells were transfected with NF-B-responsive luciferase reporter together with p65 (0.05
g) and increasing doses of FHL2 (0.1g, 0.3g, and 0.6g). TK-renilla was used as the internal control. The basal activity of the NF-B reporter cotransfected
with empty vector was arbitrarily set at 1. Data are presented as mean induction in luciferase activity 
 SD from duplicate samples. The results shown are
representative of those from more than three independent assays. *, P 	 0.05; **, P 	 0.005. (B and C) Loss of FHL2 delays NF-B nuclear translocation.
Wild-type and FHL2/ mouse embryonic fibroblasts (MEF) were stimulated with 1 g/ml LPS for 0, 5, 15, and 30 min, followed by extraction of nuclear
proteins. (B) RelA/p65 expression was analyzed by Western blotting. Nucleophosmin (NPM) was used as a loading control. Signal intensities were plotted relative
to 0-h values. (C) The value of p65 expression at 0 min was arbitrarily set as 1. Data are presented as the mean values
 SD from three experiments. *, P	 0.05.
(D) 293T cells were transfected with NF-B-responsive luciferase reporter (0.05 g) together with TRAF6 (0.05 g) or C70A and increasing doses of FHL2 (0.1
g, 0.3g, and 0.6g). *, P	 0.05; **, P	 0.005. (E) NF-B reporter assay in 293T cells transduced with control (shCtl) or TRAF6 (shTRAF6) shRNA lentiviral
vectors. TRAF6 expression in 293T cells transduced with shCtl and shTRAF6 was analyzed by Western blotting (inset). Cells were transfected with either NF-B
wt or mutated reporter (mu) along with increasing doses of FHL2 (Western blots at the bottom). The basal activity of NF-B wt reporter in cells transduced with
shCtl was arbitrarily set at 1. Data are presented as mean induction in luciferase activity
 SD from duplicate samples. *,P	 0.05. (F and G) FHL2 overexpression
increases the stability of TRAF6. 293T cells were transfected with empty vector or FHL2 and treated with cycloheximide as indicated. (F) Endogenous TRAF6 was
analyzed by Western blotting. Signal intensities were plotted relative to 0-h values. (G) The value of TRAF6 expression at 0 h was arbitrarily set as 100. Data are
presented as the mean values
 SD from three experiments. *, P	 0.05. CHX, cycloheximide.
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ited lower levels of cell death at the 6-h time point (Fig. 7E and F).
Taken together, loss of FHL2 diminishes STAT3 activation, hepa-
tocyte proliferation, and apoptosis, which may account for the
reduced susceptibility of FHL2/ mice to DEN-induced hepato-
carcinogenesis.
DISCUSSION
FHL2 has been shown to inhibit NF-B activity in osteoclastogen-
esis (13). However, increasing evidence suggests that FHL2 has a
dual role of both activating and suppressing NF-B signaling in a
cell context-dependent fashion (16, 17). Our results show that
FHL2 acts as a positive regulator of NF-B signaling in the liver at
early phases of proliferative response and in chemical carcinogen-
induced DNA damage in vivo. Loss of FHL2 produces inhibitory
effects on liver regeneration by attenuating the activation of
NF-B in hematopoietic-derived cells during the initial stages of
hepatic injury. Liver injury increases the levels of LPS originating
from commensal intestinal bacteria in the portal circulation (35).
The attenuated initial phase of inflammatory signaling in
FHL2/ livers after partial hepatectomy correlates with reduced
production of inflammatory cytokines by FHL2/ macrophages
in response to LPS in vitro, suggesting that the hyporesponsiveness
of FHL2/mice to hepatic injury might be mediated by suppres-
sion of TLR-induced NF-B activity. However, this inhibitory ef-
fect is apparently insufficient to effectively restrain liver weight
restoration, possibly because there exist redundant mechanisms
that may functionally compensate for FHL2 deficiency. These
findings underline the importance of the homeostatic functions of
FHL2 in controlling NF-B signaling for the regulation of cyto-
kine production and hepatocyte proliferation.
Although the molecular mechanisms governing FHL2 involve-
ment in NF-B signaling are still unfolding, it is likely that the
effects of FHL2 deficiency are operated, at least partly, by the sup-
pression of TRAF6 activity. Activation of NF-B signaling by
TRAF6 requires polyubiquitination of TRAF6 through lysine 63
(K63) (39), which initiates phosphorylation and ubiquitination
cascades in the downstream effectors, including TAK1, IB, and
IKK (40). The activity of these downstream effectors might be
regulated by the interaction of FHL2 with TRAF6 and subsequent
stabilization of TRAF6 by FHL2, which are needed for full trans-
mission of signals that activate NF-B, as abrogation of FHL2
delayed NF-B nuclear translocation. FHL2 is known to interact
with several RING domain E3s. Recently, we have shown that
FHL2 inhibits assembly of ubiquitin chains K27 and K63 on the E3
ligase Arkadia, a regulator of TGF- signaling (41). In the case of
TRAF6, we did not observe any change of ubiquitination patterns
provoked by FHL2 (data not shown). Further studies are required
for elucidating the regulatory mechanisms. Functional specificity
of FHL2 and TRAF6 cooperation in the balance between activa-
tion and inhibition of NF-B signaling depending on environ-
mental cues, such as osteoclastogenesis stimulated by RANK li-
gand, may explain the context-dependent and seemingly
paradoxical effects of FHL2 on NF-B signaling that have been
reported (13). Interestingly, FHL2 is also a target of TRAF6 (42),
which adds another layer of complexity in biological output of
FHL2 relating to TRAF6.
In addition to the well-established role of FHL2 in both prolif-
eration and apoptosis (27, 43), FHL2 is also associated with onco-
genesis and cancer malignancies (24, 44). Loss of FHL2 displays
inhibitory effects on liver carcinogenesis almost as effective as de-
letion of IKK in suppressing DEN-induced tumorigenesis. A
previous report has demonstrated that hepatocyte proliferation in
TABLE 1 Decreased susceptibility to DEN-induced carcinogenesis in
FHL2/ mice
Mouse
sex Genotype
No. of mice
studied
% (no.) of mice
with tumors P
Male FHL2/ 14 71.4 (10) 	0.0005
C57B 8 100 (8)
Female FHL2/ 16 18.7 (3) 	0.005
C57B 11 45.4 (5)
Total FHL2/ 30 43.3 (13) 	0.005
C57B 19 68.4 (13)
FIG 6 Hepatocarcinogenesis in wt and FHL2/ mice 8 months after DEN
exposure. H&E staining of nontumor liver parenchyma (A and B) and tumors
(T) of various size (dotted lines), randomly distributed in the liver parenchyma
(C and D) and tumor cells (E and F). (G) Activation of FHL2 expression in
DEN-induced tumors developed in wt mice analyzed by real-time RT-PCR.
The data are presented as mean values in FHL2 expression
 SD from 5 mice.
NT, nontumor; T, tumor; RP, remaining parenchyma.
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response to DEN exposure that induces DNA damage depends on
cytokines, including TNF and IL-6, which are produced in an
NF-B-dependent manner. These cytokines promote surviving
DEN-initiated hepatocytes, resulting in tumor development (21).
Accordingly, a defect of TNF and IL-6 production in FHL2/
mice constitutes a mechanism for reduced susceptibility to DEN-
induced carcinogenesis. We have previously shown that defi-
ciency of FHL2 decreases cell proliferation, whereas overexpres-
sion of FHL2 in hepatocytes induces cell growth and apoptosis
(24, 27). It is thus also possible that loss of FHL2 constrains neo-
plastic transformation through the growth-suppressive proper-
ties. These results support the proposal of a role for FHL2 as a key
mediator of NF-B activation in the liver and an important com-
ponent of regulatory mechanisms in liver carcinogenesis.
ACKNOWLEDGMENTS
We thank Hui-Kuan Lin for providing TRAF6 expression vectors, Char-
lène Blanchet, Anne Leroux, Martine Fanton d’Andon, Catherine Fitting,
and Mathieu Medina for technical help, and Monique Fabre, Jean-Marc
Cavaillon, Marie-Louise Michel, and Christine Neuveut for insightful dis-
cussion.
This work was funded in part by the French Ligue Contre le Cancer,
Comité d’Ile-de-France, the Association pour la Recherche sur le Cancer,
and Institut National du Cancer. J.D. was supported by the French
Ministère de l’Enseignement Supérieur et de la Recherche, and Y.N. was
supported by the Cancéropôle Ile-de-France.
REFERENCES
1. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M. 2006.
The multifunctional roles of the four-and-a-half-LIM only protein FHL2.
Cell. Mol. Life Sci. 63:268 –284.
2. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer
T, Holubarsch C, Buettner R, Schule R. 2000. FHL2, a novel tissue-
specific coactivator of the androgen receptor. EMBO J. 19:359 –369.
3. Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, Kurihara I, Saito
I, Saruta T. 2004. FHL2, UBC9, and PIAS1 are novel estrogen receptor
alpha-interacting proteins. Endocr. Res. 30:617– 621.
4. Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, Zhang H,
Lin J, Cheng L, Qin X, Niu C, Yuan B, Wang X, Zhu C, Zhou Y, Li J,
Song H, Huang C, Ye Q. 2009. Human four-and-a-half LIM family
FIG 7 Loss of FHL2 reduces hepatocyte proliferation after DEN exposure. (A) Liver RNA was extracted at the indicated times after DEN injection. The levels of
IL-6, TNF, and FHL2 expression were determined by real-time RT-PCR. (B) Livers from DEN-exposed mice were isolated at the indicated times and homog-
enized. Phosphorylation of STAT3 was analyzed by Western blotting. (C) Immunohistochemistry on liver sections with Ki-67 antibody. (D) Reduced DNA
synthesis in FHL2/ livers 24 h and 48 h after DEN exposure as determined by Ki-67 immunostaining. **, P	 0.005; ***, P	 0.0005. Apoptosis was detected
by TUNEL. (E) Apoptosis was detected by TUNEL. (F) Quantification of TUNEL-positive cells in wt and FHL2/ livers 6 h, 15 h, 24 h, or 48 h after DEN
exposure. *, P	 0.05.
FHL2 Participates in NF-B Signal Transduction
August 2013 Volume 33 Number 16 mcb.asm.org 3307
members suppress tumor cell growth through a TGF-beta-like signaling
pathway. J. Clin. Invest. 119:349 –361.
5. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S,
Stavnezer E, Campisi J, Fisher DE, Ben-Ze’ev A, Medrano EE. 2003. SKI
activates Wnt/beta-catenin signaling in human melanoma. Cancer Res.
63:6626 – 6634.
6. Xia T, Levy L, Levillayer F, Jia B, Li G, Neuveut C, Buendia MA, Lan
K, Wei Y. 2013. The four and a half LIM-only protein 2 (FHL2) activates
transforming growth factor beta (TGF-beta) signaling by regulating ubiq-
uitination of the E3 ligase Arkadia. J. Biol. Chem. 288:1785–1794.
7. Morlon A, Sassone-Corsi P. 2003. The LIM-only protein FHL2 is a
serum-inducible transcriptional coactivator of AP-1. Proc. Natl. Acad.
Sci. U. S. A. 100:3977–3982.
8. Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kuhl M,
Behrens J, von der Mark K, Starzinski-Powitz A, Wixler V. 2002. The
LIM-only protein FHL2 interacts with beta-catenin and promotes differ-
entiation of mouse myoblasts. J. Cell Biol. 159:113–122.
9. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X,
Flajolet M, Prigent S, Buendia MA. 2003. Identification of the LIM
protein FHL2 as a coactivator of beta-catenin. J. Biol. Chem. 278:5188 –
5194.
10. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y. 2004. Inter-
action and functional cooperation between the LIM protein FHL2, CBP/
p300, and beta-catenin. Mol. Cell. Biol. 24:10689 –10702.
11. Brun J, Fromigue O, Dieudonne FX, Marty C, Chen J, Dahan J, Wei Y,
Marie PJ. 2012. The LIM-only protein FHL2 controls mesenchymal cell
osteogenic differentiation and bone formation through Wnt5a and
Wnt10b. Bone 53:6 –12.
12. Mille F, Thibert C, Fombonne J, Rama N, Guix C, Hayashi H, Corset
V, Reed JC, Mehlen P. 2009. The patched dependence receptor triggers
apoptosis through a DRAL-caspase-9 complex. Nat. Cell Biol. 11:739 –
746.
13. Bai S, Kitaura H, Zhao H, Chen J, Muller JM, Schule R, Darnay B,
Novack DV, Ross FP, Teitelbaum SL. 2005. FHL2 inhibits the activated
osteoclast in a TRAF6-dependent manner. J. Clin. Invest. 115:2742–2751.
14. Hayden MS, Ghosh S. 2012. NF-kappaB, the first quarter-century: re-
markable progress and outstanding questions. Genes Dev. 26:203–234.
15. Smale ST. 2011. Hierarchies of NF-kappaB target-gene regulation. Nat.
Immunol. 12:689 – 694.
16. Wong CH, Mak GW, Li MS, Tsui SK. 2012. The LIM-only protein FHL2
regulates interleukin-6 expression through p38 MAPK mediated NF-
kappaB pathway in muscle cells. Cytokine 59:286 –293.
17. Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D. 2002.
TUCAN/CARDINAL and DRAL participate in a common pathway for
modulation of NF-kappaB activation. FEBS Lett. 521:165–169.
18. Sun B, Karin M. 2008. NF-kappaB signaling, liver disease and hepato-
protective agents. Oncogene 27:6228 – 6244.
19. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. 1995. Embryonic
lethality and liver degeneration in mice lacking the RelA component of
NF-kappa B. Nature 376:167–170.
20. Liu F, Xia Y, Parker AS, Verma IM. 2012. IKK biology. Immunol. Rev.
246:239 –253.
21. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. 2005. IKKbeta couples
hepatocyte death to cytokine-driven compensatory proliferation that pro-
motes chemical hepatocarcinogenesis. Cell 121:977–990.
22. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R,
Roskams T, Trautwein C, Pasparakis M. 2007. Deletion of NEMO/
IKKgamma in liver parenchymal cells causes steatohepatitis and hepato-
cellular carcinoma. Cancer Cell 11:119 –132.
23. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S,
Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. 2004.
NF-kappaB functions as a tumour promoter in inflammation-associated
cancer. Nature 431:461– 466.
24. Nouet Y, Dahan J, Labalette C, Levillayer F, Julien B, Jouvion G, Cairo
S, Vives FL, Ribeiro A, Huerre M, Colnot S, Perret C, Nhieu JT,
Tordjmann T, Buendia MA, Wei Y. 2012. The four and a half LIM-only
protein 2 regulates liver homeostasis and contributes to carcinogenesis. J.
Hepatol. 57:1029 –1036.
25. Chu PH, Bardwell WM, Gu Y, Ross J, Jr, Chen J. 2000. FHL2 (SLIM3)
is not essential for cardiac development and function. Mol. Cell. Biol.
20:7460 –7462.
26. Nicou A, Serriere V, Prigent S, Boucherie S, Combettes L, Guillon G,
Alonso G, Tordjmann T. 2003. Hypothalamic vasopressin release and
hepatocyte Ca2 signaling during liver regeneration: an interplay stimu-
lating liver growth and bile flow. FASEB J. 17:1901–1903.
27. Labalette C, Nouet Y, Sobczak-Thepot J, Armengol C, Levillayer F,
Gendron MC, Renard CA, Regnault B, Chen J, Buendia MA, Wei Y.
2008. The LIM-only protein FHL2 regulates cyclin D1 expression and cell
proliferation. J. Biol. Chem. 283:15201–15208.
28. Cougot D, Allemand E, Riviere L, Benhenda S, Duroure K, Levillayer F,
Muchardt C, Buendia MA, Neuveut C. 2012. Inhibition of PP1 phos-
phatase activity by HBx: a mechanism for the activation of hepatitis B virus
transcription. Sci. Signal. 5:ra1.
29. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M,
Si-Tahar M. 2002. Cutting edge: the immunostimulatory activity of the
lung surfactant protein-A involves Toll-like receptor 4. J. Immunol. 168:
5989 –5992.
30. Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, Gaudin F,
Naveau S, Prevot S, Makhzami S, Perlemuter G, Cassard-Doulcier AM.
2012. Toxic lipids stored by Kupffer cells correlates with their pro-
inflammatory phenotype at an early stage of steatohepatitis. J. Hepatol.
57:141–149.
31. Taub R. 2004. Liver regeneration: from myth to mechanism. Nat. Rev.
Mol. Cell Biol. 5:836 – 847.
32. Fausto N, Laird AD, Webber EM. 1995. Liver regeneration. 2. Role of
growth factors and cytokines in hepatic regeneration. FASEB J. 9:1527–
1536.
33. Teramoto K, Bowers JL, Khettry U, Palombo JD, Clouse ME. 1993. A rat
fatty liver transplant model. Transplantation 55:737–741.
34. Weltman MD, Farrell GC, Liddle C. 1996. Increased hepatocyte CYP2E1
expression in a rat nutritional model of hepatic steatosis with inflamma-
tion. Gastroenterology 111:1645–1653.
35. Cornell RP, Liljequist BL, Bartizal KF. 1990. Depressed liver regenera-
tion after partial hepatectomy of germ-free, athymic and lipopolysaccha-
ride-resistant mice. Hepatology 11:916 –922.
36. He G, Karin M. 2011. NF-kappaB and STAT3— key players in liver
inflammation and cancer. Cell Res. 21:159 –168.
37. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin
M. 2007. Gender disparity in liver cancer due to sex differences in MyD88-
dependent IL-6 production. Science 317:121–124.
38. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W,
Peck-Radosavljevic M, Leffert HL, Karin M. 2010. Hepatocyte IKKbeta/
NF-kappaB inhibits tumor promotion and progression by preventing ox-
idative stress-driven STAT3 activation. Cancer Cell 17:286 –297.
39. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C,
Pickart C, Chen ZJ. 2000. Activation of the IkappaB kinase complex by
TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a
unique polyubiquitin chain. Cell 103:351–361.
40. Chen ZJ. 2005. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell
Biol. 7:758 –765.
41. Hubbi ME, Gilkes DM, Baek JH, Semenza GL. 2012. Four-and-a-half
LIM domain proteins inhibit transactivation by hypoxia-inducible factor
1. J. Biol. Chem. 287:6139 – 6149.
42. Bai S, Zha J, Zhao H, Ross FP, Teitelbaum SL. 2008. Tumor necrosis
factor receptor-associated factor 6 is an intranuclear transcriptional co-
activator in osteoclasts. J. Biol. Chem. 283:30861–30867.
43. Qian Z, Mao L, Fernald AA, Yu H, Luo R, Jiang Y, Anastasi J, Valk PJ,
Delwel R, Le Beau MM. 2009. Enhanced expression of FHL2 leads to
abnormal myelopoiesis in vivo. Leukemia 23:1650 –1657.
44. Labalette C, Nouet Y, Levillayer F, Colnot S, Chen J, Claude V, Huerre
M, Perret C, Buendia MA, Wei Y. 2010. Deficiency of the LIM-only
protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice. PLoS
One 5:e10371. doi:10.1371/journal.pone.0010371.
Dahan et al.
3308 mcb.asm.org Molecular and Cellular Biology
